The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
1694
January 22, 2024
View Complete Issue         Table of Contents 2019 
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
January 22, 2024 (Issue: 1694)
The FDA has approved the complement C5 inhibitor avacincaptad pegol (Izervay – Iveric) for intravitreal treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD). Avacincaptad pegol is the second...more
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Avacincaptad Pegol (Izervay) for Geographic Atrophy in Age-Related Macular Degeneration
Article code: 1694d
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.